Bayer AG (BAYN) Given Consensus Rating of “Buy” by Brokerages

Shares of Bayer AG (FRA:BAYN) have earned a consensus recommendation of “Buy” from the twenty-two research firms that are covering the company, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a hold recommendation and fifteen have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is €96.88 ($112.65).

A number of equities analysts recently commented on the company. Baader Bank set a €123.00 ($143.02) target price on Bayer and gave the company a “buy” rating in a report on Friday. Commerzbank set a €99.00 ($115.12) target price on Bayer and gave the company a “buy” rating in a report on Thursday. Deutsche Bank set a €127.00 ($147.67) target price on Bayer and gave the company a “buy” rating in a report on Friday, November 2nd. JPMorgan Chase & Co. restated a “buy” rating and set a target price on shares of Bayer in a report on Friday, November 2nd. Finally, Sanford C. Bernstein set a €90.00 ($104.65) price target on Bayer and gave the company a “buy” rating in a research report on Thursday, November 1st.

Bayer stock traded up €0.28 ($0.33) during midday trading on Monday, reaching €71.00 ($82.56). 2,505,231 shares of the stock traded hands. Bayer has a 12-month low of €91.58 ($106.49) and a 12-month high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Story: What Is An Exchange-Traded Fund (ETF)?

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply